- Manufactured by recombinant DNA technology1
- Calcitonin-salmon has been shown to reduce
the risk of
new vertebral fractures by one-third*2
- Multiple studies demonstrate additional calcitonin-salmon
efficacy
- Shown to increase vertebral bone mineral density (BMD)
by an average of 3% (95% CI: 1.8%-4.2%)
from baseline†3
- Shown to reduce the risk of bone loss by 81% vs
placebo‡4
- Shown to rapidly decrease plasma markers of bone resorption
as early as 1 month of use5
- Shown to preserve or improve trabecular microarchitecture§6
- Well tolerated with no known drug interactions#1
- Dosing and administration convenience
- One spray (200 IU) QD, alternating nostrils daily
- 3.7-mL bottle contains enough medication for 30 days
- No waiting with regard to eating or drinking
- No administration advisories against coffee, juice, or
any other beverage
- No need to stand or remain upright after administration,
which makes bedtime dosing possible
|
|
 |
